Literature DB >> 9350753

Effects of specimen collection, processing, and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma.

C C Ginocchio1, X P Wang, M H Kaplan, G Mulligan, D Witt, J W Romano, M Cronin, R Carroll.   

Abstract

To define the optimal blood collection parameters for plasma human immunodeficiency virus type 1 (HIV-1) viral load testing, plasma HIV-1 RNA levels were quantitated with the NASBA HIV-1 RNA QT System from blood specimens that were collected, processed, and stored under a variety of conditions that might have affected HIV-1 RNA stability. We determined that when whole blood was processed within 2 h of specimen collection the levels of HIV-1 RNA detected in EDTA-, heparin-, and acid citrate dextrose (ACD)-anticoagulated plasma samples were comparable. The levels of HIV-1 RNA in serum specimens (mean = 4.126 log units) were significantly lower (P < 0.01) than the levels in corresponding plasma samples (mean = 4.501 log units). One cycle of freeze-thaw (-70 degrees C) did not significantly reduce the level of HIV-1 RNA detected in EDTA-, heparin-, or ACD-anticoagulated plasmas. The EDTA-anticoagulated plasmas showed the smallest decrease in HIV-1 RNA copies (0.050 log units). HIV-1 RNA levels decreased over a 6-month time period in serum as well as in EDTA-, ACD-, and heparin-anticoagulated plasmas stored at -70 degrees C. However, the only significant decreases were for serum (mean decrease = 0.317 log units) and heparin-anticoagulated samples (mean decrease = 0.384 log units). A comparison of the levels of HIV-1 RNA in cell-free plasma collected in VACUTAINER EDTA Plasma Preparation Tubes and in standard VACUTAINER EDTA tubes determined that HIV-1 RNA levels were stable for up to 30 h after collection when stored at either room temperature (mean standard deviation [SD] = +/- 0.101 log units) or at 4 degrees C (mean SD = +/- 0.102 log units) as cell-free plasma or as EDTA-anticoagulated whole blood (mean SD = +/- 0.109 log units). These data indicate that EDTA-anticoagulated plasma is the most suitable and stable matrix for HIV-1 RNA quantitation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9350753      PMCID: PMC230081          DOI: 10.1128/jcm.35.11.2886-2893.1997

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV monitor test.

Authors:  A M Vandamme; J C Schmit; S Van Dooren; K Van Laethem; E Gobbers; W Kok; P Goubau; M Witvrouw; W Peetermans; E De Clercq; J Desmyter
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-10-01

2.  Effect of platelet-associated virus on assays of HIV-1 in plasma.

Authors:  T H Lee; R R Stromberg; D Henrard; M P Busch
Journal:  Science       Date:  1993-12-03       Impact factor: 47.728

3.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.

Authors:  M Piatak; M S Saag; L C Yang; S J Clark; J C Kappes; K C Luk; B H Hahn; G M Shaw; J D Lifson
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

4.  Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy.

Authors:  M Holodniy; D Katzenstein; M Winters; J Montoya; R Shafer; M Kozal; M Ragni; T C Merigan
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-04

5.  Infectious decay of human immunodeficiency virus type 1 in plasma.

Authors:  T Moudgil; E S Daar
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

6.  Inhibition of human immunodeficiency virus gene amplification by heparin.

Authors:  M Holodniy; S Kim; D Katzenstein; M Konrad; E Groves; T C Merigan
Journal:  J Clin Microbiol       Date:  1991-04       Impact factor: 5.948

7.  Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection.

Authors:  A C Collier; R W Coombs; M A Fischl; P R Skolnik; D Northfelt; P Boutin; C J Hooper; L D Kaplan; P A Volberding; L G Davis; D R Henrard; S Weller; L Corey
Journal:  Ann Intern Med       Date:  1993-10-15       Impact factor: 25.391

8.  Cell-free plasma human immunodeficiency virus type 1 titer assessed by culture and immunocapture-reverse transcription-polymerase chain reaction.

Authors:  R W Coombs; D R Henrard; W F Mehaffey; J Gibson; E Eggert; T C Quinn; J Phillips
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

Review 9.  Viral markers in HIV infection and AIDS.

Authors:  A L Cunningham; D E Dwyer; D N Dowton
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993

10.  Viricidal effect of polymorphonuclear leukocytes on human immunodeficiency virus-1. Role of the myeloperoxidase system.

Authors:  S J Klebanoff; R W Coombs
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

View more
  30 in total

Review 1.  Monitoring patients with HIV disease.

Authors:  M Helbert; J Breuer
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

2.  Obtaining unacceptable results in assays for quantitation of human immunodeficiency virus type 1 RNA in plasma samples.

Authors:  A Aguilera; A Vela; M Treviño; E Varela; R Seoane; B J Regueiro
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

3.  Investigation of effects of acid citrate dextrose and EDTA on ability to quantitatively culture human immunodeficiency virus.

Authors:  C Jennings; J W Bremer; D J Brambilla
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

4.  Comparison of blood collected in acid-citrate-dextrose and EDTA for use in human immunodeficiency virus peripheral blood mononuclear cell cultures.

Authors:  S A Fiscus; H Chakraborty; R Shepard; M Goodman
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

5.  Stability of hepatitis C virus, HIV, and hepatitis B virus nucleic acids in plasma samples after long-term storage at -20°C and -70°C.

Authors:  Cristina Baleriola; Harpreet Johal; Brendan Jacka; Sandra Chaverot; Scott Bowden; Sara Lacey; William Rawlinson
Journal:  J Clin Microbiol       Date:  2011-07-13       Impact factor: 5.948

6.  Influence of increased CD4 cell counts on the genetic variability of hepatitis C virus in patients co-infected with human immunodeficiency virus I.

Authors:  Xue-Ping Wang; Leslie Goodwin; Pamela Kahn; Craig Gawel; Cheston B Cunha; Benjamin Laser; Benjamin Sahn; Mark H Kaplan
Journal:  J Biomol Tech       Date:  2006-07

Review 7.  Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop Attendees. Technology Utilization for HIV-1 Blood Evaluation and Standardization in Pediatrics.

Authors:  J Lew; P Reichelderfer; M Fowler; J Bremer; R Carrol; S Cassol; D Chernoff; R Coombs; M Cronin; R Dickover; S Fiscus; S Herman; B Jackson; J Kornegay; A Kovacs; K McIntosh; W Meyer; N Michael; L Mofenson; J Moye; T Quinn; M Robb; M Vahey; B Weiser; T Yeghiazarian
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

8.  Biospecimen reporting for improved study quality (BRISQ).

Authors:  Helen M Moore; Andrea B Kelly; Scott D Jewell; Lisa M McShane; Douglas P Clark; Renata Greenspan; Daniel F Hayes; Pierre Hainaut; Paula Kim; Elizabeth Mansfield; Olga Potapova; Peter Riegman; Yaffa Rubinstein; Edward Seijo; Stella Somiari; Peter Watson; Heinz-Ulrich Weier; Claire Zhu; Jim Vaught
Journal:  J Proteome Res       Date:  2011-06-21       Impact factor: 4.466

9.  Relationship of incremental specimen volumes and enhanced detection of human immunodeficiency virus type 1 RNA with nucleic acid amplification technology.

Authors:  D J Witt; M Kemper; A Stead; C C Ginocchio; A M Caliendo
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

10.  Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands.

Authors:  Luuk Gras; Suzanne Jurriaans; Margreet Bakker; Ard van Sighem; Daniela Bezemer; Christophe Fraser; Joep Lange; Jan M Prins; Ben Berkhout; Frank de Wolf
Journal:  PLoS One       Date:  2009-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.